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SUMMARY  
Background: Health Related Quality of Life (HRQL) 
measures can capture the non-respiratory effects of 
Chronic Obstructive Pulmonary Disease (COPD). 
However the relationship with Peak Expiratory Flow 
(PEF) is not well understood 
Aim: To determine the relationship of PEF and quality 
of life measurements in patients with COPD 
Settings and Design: A cross section of consecutive 
patients in a university clinic 
Methods: Stable patients with COPD defined by the 
Global Initiative on chronic Obstructive Lung Disease 
(GOLD) criteria, were recruited into the study. Spi-
rometry was done using American Thoracic Society’s 
standards and reference equations from African Ameri-
can norms of the US population. Quality of life was 
measured with the St George’s Respiratory Question-
naire (SGRQ) 
Results: Out of 50 patients recruited for the study, 48 
provided complete data with acceptable spirometry and 
PEF data. The mean (SD) age and body mass index 
was 68.4 (8.9) years and 21.4 (4.6) kg/m2 respectively 
and 96% of the patients were in moderate-severe stages 
of COPD using the GOLD criteria. Percent predicted 
PEF correlated with percent predicted FEV1; r= 0.559 
p<0.001 and also showed a significant, though moder-
ate correlation between PEF readings and SGRQ scores 
especially in the activity (r= -0.455 p< 0.01) and total 
scores (r=-0.415 p<0.01) for pre bronchodilator (BD) 
percent predicted PEF. In regression analysis, PEF was 
associated with SGRQ (-0.11 95% CI -0.19, -0.03) 
after adjusting for age, sex, height, smoking and dis-
ease severity 
Conclusions: PEF correlates with SGRQ scores and 
may be a useful surrogate for HRQL in patients with 
COPD 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a 
respiratory disorder of significant public health im-
portance. It is presently ranked as the third most im-
portant cause of death worldwide.1 A diagnosis of 
COPD is established by a post bronchodilator (BD) 
forced expiratory volume in the first second 
(FEV1)/forced vital capacity (FVC) ratio of less than 
0.7 2 or the lower limit of normal (LLN).3 It is largely 
under diagnosed in developing countries for various 
reasons including lack of affordable spirometers in 
primary care settings.4  
 
Though the peak flow meter have been dismissed as 
unreliable for diagnosing COPD,5,6 recent reports sug-
gests that peak flow measurements may be an inexpen-
sive way of screening7 and initial identification of se-
vere cases of COPD for subsequent confirmatory spi-
rometry.8,9  However COPD is a multi-systemic disease 
with extra-pulmonary manifestations that often elude 
spirometric assessment.10,11  
 
Quality of life is an important criterion in the assess-
ment of the impact and treatment outcome in patients 
with COPD. Quality of life scores assess an individu-
al’s ability to perform and derive satisfaction from ac-
tivities of daily living such as social role functioning, 
home management, social and family relationships, 










Quality of life questionnaires are commonly used to 
capture the non-respiratory manifestations of COPD 
but they are often difficult to complete in busy clinics 
especially in low literacy settings as in many develop-
ing countries.  Peak flow meters could potentially serve 
as tools both for screening and for providing a measure 
of health related quality of life in COPD. It is thus im-
perative to understand how measures of peak expirato-
ry flow (PEF) relate with quality of life scores.  
 
We undertook a cross sectional assessment of patients 
with COPD to determine the relationship between PEF 
and quality of life measurements using the St George’s 




It was a cross sectional study. Stable patients with 
COPD were recruited consecutively from the outpa-
tient respiratory clinic of Obafemi Awolowo Universi-
ty (OAU) teaching hospital, Ile-Ife, Nigeria.  Inclusion 
criteria included a previous diagnosis of COPD based 
on a post bronchodilator FEV1/FVC ratio below 0.7. 
Patients were also further categorized into stages of 
disease severity using the criteria defined by the Global 
initiative for chronic Obstructive Lung Disease 
(GOLD). 2 
 
Patients were judged as stable if there was no history of 
recent worsening of symptoms, hospitalization or 
change in their medications over the preceding six 




Health related quality of life (HRQL) was assessed 
using the St George’s Respiratory Questionnaire 
(SGRQ).13 The SGRQ is a weighted questionnaire that 
has been shown to be valid, reliable and reproducible 
in patients with COPD. It contains 50 items with 76 
weighted responses that cover three domains: symp-
toms – distress due to respiratory symptoms, activity – 
disturbances of physical activity and impact – overall 
impact on daily life and well-being.   
 
In addition to the domain scores, there is also a total 
score.14 The SGRQ is scaled from zero to 100 (with 
zero representing the best health-related quality of life). 
This questionnaire, which was forward and back trans-
lated in Yoruba language, was administered to each 
participant face to face by a trained interviewer.   
 
Lung function 
The FEV1 and FVC were measured using a standard-
ized bellows spirometer (Vitalograph Ltd, Bucking-
ham, England. 1997, Model 2150).   
The PEF was measured using the mini-Wright peak 
flow meter.15, 16 The parameters were assessed before 
and 20 minutes after the inhalation of 400µg of Salbut-
amol using a metered dose inhaler (MDI) and a spacer 
device.  For spirometry, a minimum of three and a 
maximum of eight spirometry maneuvers were done 
according to ERS/ATS criteria.17 The best three ac-
ceptable and reproducible maneuvers (within 200ml) 
were recorded for each patient.   
 
For measurement of peak expiratory flow, patients 
were instructed to inhale to total lung capacity and ex-
hale with a forceful blast. Three measurements were 
made and the best was recorded. The reference equa-
tion for the spirometry and PEF was derived from the 
African American norms of the third National Health 
and Nutrition Examination Survey (NHANES III).18 
 
Other measurements 
Height was measured without shoes to the nearest cen-
timeter using a wall-mounted stadiometer while weight 
was measured without outer garment to the nearest 0.1 
kilogram using a portable weight scale after zero cali-
bration check.  
 
Data analysis 
The data was analyzed using Stata 11.2 statistical 
package (Stata Corp., College Station, TX, USA).19 
Continuous data were presented as means and standard 
deviations while categorical and discrete data were 
presented using proportions and frequencies. The 
SGRQ data was analyzed using the excel-based 
weighted scoring calculator developed in St George’s 
Hospital.  
 
Correlation coefficients between peak expiratory flow 
and the domains scores of the SGRQ was determined 
using spearman’s correlation. Multiple linear regres-
sions was used to determine the independent effect of 
PEF on SGRQ quality of life total scores after adjust-
ing for the following co-variates- age, sex, height, 
smoking status and GOLD classification of disease 
severity. The best model was determined by changes in 
R squared value. 
 
Ethical Clearance 
The study protocol was approved by the ethics commit-
tee of Obafemi Awolowo University teaching hospital. 




Out of 50 patients recruited for the study, 48 provided 
complete data with acceptable spirometry and PEF data 
and were included in the analysis.  
 
 




The general characteristics of the patients included in 
the final analysis are shown in Table 1.  
 
Forty percent of the respondents were female. The 
mean (SD) age and body mass index of the study popu-
lation was 68.4 (8.9) years and 21.4 (4.6) kg/m2 respec-
tively. Fifty two percent of the patients had never 
smoked cigarette and almost all (96 %) of the patients 
were at least in moderate-severe stages of COPD using 
the GOLD criteria. 
 
Table 1 Characteristics of the study participants 
Variable Mean ± SD or n (%) 
Age (years) 68.4 ± 8.9 
Height (cm) 161.9 ± 8.9 
BMI (Kg/m2) 21.4 ± 4.6 
Smoking Status  
    Never 25 (52) 
    Previous 23 (48) 
    Current - 
GOLD Classification  
    Mild 2 (4) 
    Moderate 12 (25) 
    Severe 20 (42) 
    Very Severe 14 (29) 
SD - Standard Deviation; BMI – Body Mass Index; GOLD- Global 
initiative for chronic Obstructive Lung Disease 
Post bronchodilator FEV1/FVC <0.7 & FEV1 ≥ 80% predicted 
(Mild); 50% <= FEV1 < 80% predicted (Moderate); 30% <=FEV1 < 
50% predicted (Severe); FEV1 < 30% predicted (Very Severe). 
Proportions reported are based on the entire sample of patients. 
 
Sixty five percent of the patients had peak flow read-
ings below the acceptable lower limit of normal (LLN) 
for their age and height (Table 2). The mean (SD) of 
predicted post bronchodilator (post BD) PEF, FEV1, 
FVC and FEV1/FVC were 67.5 % (30.7), 40.7 % 
(17.4), 59.9 % (26.1) and 67.7 % (14.1) respectively. 
 
In addition, there was a significant, though moderate 
correlation between PEF readings and SGRQ scores 
(Table 3). However the correlation between FEV1 and 
SGRQ scores were weak and generally not significant 
(Data not shown). The correlation between PEF and 
SGRQ was best in the activity and total scores.  
 
The coefficients in the SGRQ activity score were r= - 
0.453 p<0.01 (pre BD PEF (l/min)), r= -0.455 p< 0.01 
(pre BD % PEF), r= -0.469 p<0.001  (post BD PEF 
(l/min)) and r= -0.450 p<0.01 (post BD % PEF). The 
coefficients for the total scores were r=-0.370 p<0.01, 
r=-0.415 p<0.01, r=-0.435 p<0.01 and r=-0.431 p<0.01 
for pre BD PEF l/min, pre BD % PEF, post BD PEF 
l/min and post BD % PEF respectively.  
Peak expiratory flow was associated with SGRQ (-0.11 
95% CI -0.19, -0.03) after adjusting for age, sex, 
height, smoking status and GOLD classification of 
severity (Table 4). This model explained 17% of the 
variability in SGRQ total score. 
 
Table 2 Lung function and SGRQ scores of the partic-
ipants 
Variable Mean ± SD or  % (SE) 
Pre BD PEF L/min 217.0 ± 91.2 
Post BD PEF L/min 235.4 ± 100.6 
Pre BD PEF (% Predicted) 62.2 ± 27.7 
Post BD PEF (% Predicted) 67.5 ± 30.7 
Pre BD FEV1 (L) 0.8 ± 0.4 
Post BD FEV1 (L) 0.8 ± 0.4 
Pre BD FEV1 (% Predicted) 39.7 ± 18.4 
Post BD FEV1 (% Predicted) 40.7 ± 17.4 
Pre BD FVC (L) 1.5 ± 0.6 
Post BD FVC (L) 1.6 ± 0.6 
Pre BD FVC (% Predicted) 57.5 ± 23.0 
Post BD FVC (% Predicted) 59.9 ± 26.1 
Pre BD FEV1/FVC (%) 52.2 ± 10.9 
Post BD FEV1/FVC (%) 52.3 ± 11.3 
Pre BD FEV1/FVC (% Predicted) 67.5 ± 13.6 
Post BD FEV1/FVC (% Predicted) 67.7 ± 14.1 
Post BD PEF<LLN *  64.6 (6.9) 
Post BD FEV1 <LLN* 93.8 (3.5) 
Post BD FVC <LLN* 81.3 (5.6) 
Post BD FEV1/FVC <LLN* 91.6 (4.0) 
SGRQ – Symptom 45.4 ± 26.9 
SGRQ – Activity 49.3 ± 29.1 
SGRQ – Impact 29.1 ± 19.9 
SGRQ – Total 38.0 ± 22.1 
Standard Deviation, SE – Standard Error, SGRQ - St George’s Res-
piratory Questionnaire, BD – Bronchodilator, FEV1 – Forced expira-
tory volume in one second, FVC- Forced Vital Capacity, PEF – Peak 
Expiratory Flow, LLN – Lower Limit of Normal 
 
*Represents proportions below the LLN and standard error based on 
prediction values derived from equations for African Americans in 




Our study showed that PEFR correlates with SGRQ 
quality of life scores in patients with COPD but ex-
plains a small proportion of the variance in quality of 
life after adjusting for age, sex, height, smoking status 
and disease severity. We also found that 64% of the 
patients had peak flow readings below the lower limit 








Our study provides preliminary data on the relationship 
between PEF and quality of life in patients with COPD, 
suggesting its possible utility as a surrogate for as-






We found strong correlation between PEF and FEV1 
readings, moderate correlation between PEF and 
SGRQ but weak correlation between SGRQ and FEV1. 
 
In a previous analysis,20 we noted that the correlation 
between SGRQ scores and lung function parameters 
like FEV1 and FVC was weak, possibly suggesting that 
spirometry and quality of life are independent, albeit 
complementary modalities of evaluation of patients 
with COPD. PEF correlates with FEV1 but unlike 
FEV1, PEF also correlate with SGRQ quality of life 
scores (Table 3).  
The relationship between PEF and quality of life in 
patients with COPD is possibly connected to daily 
changes in respiratory airflow capacity, ventilatory 
ability and sense of breathlessness, which impacts sig-
nificantly on quality of life.  
 
Though the diagnosis of COPD is spirometry-based,2 it 
is worthwhile to note that there is no evidence to sug-
gest that spirometry has an advantage over PEF in the 
day-to-day monitoring or management of patients with 
COPD,21 neither is it time efficient or easier to per-
form.22  
As a result, PEF measurements, even without broncho-
dilation, could provide useful and readily accessible 
information to the general practitioner or primary care 
physicians about the daily or short-term structural 








We also observed that pre bronchodilator PEF predicts 
SGRQ quality of life score independent of age, sex, 
height, smoking status or severity of COPD. However, 
PEF explains a small percentage of the variability in 
SGRQ scores and as such, there may be other parame-
ters that also affect quality of life in COPD other than a 
simple measurement of the airflow status using a PEF 
meter.  
 
There is very sparse information on the utility of PEF 
assessment as an outcome measure in COPD. Hansen 
and colleagues showed that PEF could be used to pre-
dict survival in patients with COPD.23 They compared 
the utility of FEV1 and PEF for assessing outcome in a 
sample of 1095 patients with COPD who were initially 
enrolled in the Copenhagen City Study.23 After a dec-
ade of follow up, they found the best PEF was at least 
equal to the best FEV1 as a predictor of overall mortal-
ity in subjects with COPD, after controlling for age, 
smoking, sex, and body mass index.  They concluded 
that, “.... despite close correlation to FEV1, PEF pro-
vided independent prognostic information in patients 
with COPD”.23 The present study corroborates this 
finding and indicates that PEF may thus be invaluable 
in assessing the impact of COPD and for predicting its 
long-term outcome especially in primary care centres. 
However, there is clearly a need for large sensitivity 
studies on this subject. 
 
Interestingly, we also observed that sixty five percent 
of the patients in our study population had low lung 
function parameters (FEV1 & FVC) compared with 
predicted values using reference equations for African 
Americans. Forced vital capacity has been shown to 
correlate with survival.24 Populations with low forced 
vital capacity appear to suffer greater mortality howev-
er its determinants are poorly understood. Our popula-
tion of patients was generally of the low socioeconom-
ic class, a group known to have poor access to health 
care. It is unclear why our sample of patients had very 
low forced vital capacity and other lung parameters. 
This may probably be because the patients with COPD 
in our clinics appears quite late for treatment when they 
are already at advanced stages of the disease. Low lung 
function parameters may also suggest low maximally 
attained pre-morbid lung function and a subsequent 
rapid decline over time, a phenomenon described as 
‘horse racing’.25, 26 Though this phenomenon cannot be 
evaluated in the present cross sectional study, it war-
rants further investigation. 
 
It is important, however, to exercise caution in inter-
preting the results of the present study. Our sample 
comprised patients with moderate-severe cases of 
COPD and the results may not be applicable to all cas-
es of COPD. Our PEF measurements were obtained 
separately from spirometry test using mini-Wright peak 
flow meters. This may not be entirely comparable with 
PEF readings obtained from spirometry manoevres as 
was done is previous studies.8, 9 In addition, this study 
is limited by the small sample size. A larger study will 
provide more robust effect estimates. 
 
Notwithstanding these limitations, this study adds to 
the body of evidence that shows that PEF meters may 
be veritable tools for evaluating patients especially in 
clinic settings. It also provides a simple measure of the 
expiratory flow and large airway caliber.  
 
It is important for policy makers to encourage further 
research into the applicability of this simple and inex-
pensive device as a screening tool in COPD and as a 
marker of HRQL. This by no means suggests that spi-
rometry should be replaced by PEF in the evaluation of 
ventilation but rather, in local clinics with no access to 
quality spirometry, a measure of PEF in patients with 
severe COPD can provide a reasonably good day-to-




In conclusion we have shown that peak expiratory flow 
correlates with quality of life scores and may be an 
important simple measure for assessing both lung func-
tion and quality of life in patients with COPD in low-
income primary care settings. 
 
ACKNOWLEDGEMENT:  
We wish to express our gratitude to all the patients who 
participated in this study 
 
REFERENCES 
1. Lozano R, Naghavi M, Foreman K, Lim S, 
Shibuya K, Aboyans V, et al. Global and regional 
mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: A systematic analysis 
for the global burden of disease study 2010. The 
Lancet. 2013; 380(9859): 2095-128. 
2. GOLD - the global initiative for chronic obstruc-
tive lung disease; cited 5/29/2013. Available from: 
http://www.goldcopd.org/guidelines-global-
strategy-for-diagnosis-management.html. 
3. Swanney MP, Ruppel G, Enright PL, Pedersen 
OF, Crapo RO, Miller MR, et al. Using the lower 
limit of normal for the FEV1/FVC ratio reduces 
the misclassification of airway obstruction. Br 
Med J. 2008; 63 (12): 1046-51 
4. Salvi SS, Barnes PJ. Chronic obstructive pulmo-
nary disease in non-smokers. Lancet (London, 
England). 2009; 374 (9691): 733-43. 
 
 




5. Thiadens H, De Bock G, Van Houwelingen J, 
Dekker F, De Waal M, Springer M, et al. Can peak 
expiratory flow measurements reliably identify the 
presence of airway obstruction and bronchodilator 
response as assessed by FEV1 in primary care pa-
tients presenting with a persistent cough? Thorax. 
1999; 54 (12): 1055-60. 
6. Kelly C, Gibson G. Relation between FEV1 and 
peak expiratory flow in patients with chronic air-
flow obstruction. Thorax. 1988; 43(4): 335-6. 
7. Jackson H, Hubbard R. Detecting chronic obstruc-
tive pulmonary disease using peak flow rate: Cross 
sectional survey. BMJ. 2003; 327(7416): 653-4. 
8. Jithoo A, Enright PL, Burney P, Buist AS, Bate-
man ED, Tan WC, et al. Case-finding options for 
COPD: Results from the burden of obstructive 
lung disease study. Eur Respir J. 2013; 41 (3): 
548-55. 
9. Perez-Padilla R, Vollmer W, Vázquez-García J, 
Enright P, Menezes A, Buist A. Can a normal peak 
expiratory flow exclude severe chronic obstructive 
pulmonary disease? Int J Tuberc Lung Dis. 2009; 
13 (3): 387. 
10. Jones PW. Issues concerning health-related quality 
of life in COPD. Chest-Supplements. 1995; 107 
(5): 187S. 
11. Jones P. Health status measurement in chronic 
obstructive pulmonary disease. Thorax. 2001;56 
(11):880-7. 
12. Hütter B, Würtemberger G. [Functional capacity 
(dyspnea) and quality of life in patients with 
chronic obstructive lung disease (COPD): Instru-
ments of assessment and methodological aspects]. 
Pneumologie. 1999; 53 (3): 133-42. 
13. Jones PW, Quirk FH, Baveystock CM, Littlejohns 
P. A self-complete measure of health status for 
chronic airflow limitation. The St. George's Res-
piratory Questionnaire. Am Rev Respir Dis. 1992; 
145 (6): 1321-7. 
14. Jones PW, Quirk F, Baveystock C. The St 
George's Respiratory Questionnaire. Respir Med. 
1991; 85:25-31. 
15. Perks W, Tams I, Thompson D, Prowse K. An 
evaluation of the mini-wright peak flow meter. 
Thorax. 1979; 34 (1): 79-81. 
16. Wright B, McKerrow C. Maximum forced expira-
tory flow rate as a measure of ventilatory capacity. 
Br Med J. 1959; 2(5159): 1041. 
17. Miller MR, Hankinson J, Brusasco V, Burgos F, 
Casaburi R, Coates A, et al. Standardisation of spi-
rometry. Eur Respir J. 2005; 26(2): 319-38. 
18. Hankinson JL, Odencrantz JR, Fedan KB. Spiro-
metric reference values from a sample of the gen-
eral US population. Am J Respir Crit Care Med. 
1999; 159 (1): 179-87. 
19. StataCorp L. Stata version 11.0. College Station, 
TX: StataCorp LP. 2009. 
20. Obaseki D, Erhabor G, Awopeju O, Obaseki J, 
Adewole O. Determinants of Health Related quali-
ty of life in a sample of patients with chronic ob-
structive pulmonary disease in Nigeria using the 
St. George’s Respiratory Questionnaire. Afr 
Health Sci 2013; 13(3): 694-702. 
21. White P. Spirometry and peak expiratory flow in 
the primary care management of COPD. Pri Care 
Respir J 2004; 13(1):5-8. 
22. Bush A, Cramer D. Guidelines for the measure-
ment of respiratory function. Respir Med. 1994; 
88(10): 798. 
23. Hansen EF, Vestbo J, Phanareth K, Kok-Jensen A, 
Dirksen A. Peak flow as predictor of overall mor-
tality in asthma and chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med.. 2001; 
163(3): 690-3. 
24. Burney P, Hooper R. Forced vital capacity, airway 
obstruction and survival in a general population 
sample from the USA. Thorax. 2011; 66(1): 49-54. 
25. Peto R. The horse-racing effect. The Lancet. 1981; 
318 (8244): 467-8. 
26. Burrows B, Knudson RJ, Camilli AE, Lyle SK, 
Lebowitz MD. The" horse-racing effect" and pre-
dicting decline in forced expiratory volume in one 
second from screening spirometry. Am Rev Respir 
Dis. 1987; 135 (4): 788-93. ✪ 
 
 
